Document is current
Any future updates will be listed below
-
Authors
Fuji, Shigeo https://orcid.org/0000-0001-5118-7950
Inoue, Yoshitaka https://orcid.org/0000-0002-3967-7356
Makiyama, Junya https://orcid.org/0000-0003-0883-2920
Nakano, Nobuaki
Ito, Ayumu https://orcid.org/0000-0001-5681-6357
Kawakita, Toshiro
Eto, Tetsuya
Suehiro, Youko
Itonaga, Hidehiro
Sawayama, Yasushi
Mori, Yasuo https://orcid.org/0000-0001-6425-1720
Uchida, Naoyuki https://orcid.org/0000-0001-5952-5926
Morishima, Satoko https://orcid.org/0000-0002-7391-4271
Onizuka, Makoto https://orcid.org/0000-0003-3864-0823
Ishitsuka, Kenji https://orcid.org/0000-0002-7030-497X
Fukuda, Takahiro
Atsuta, Yoshiko https://orcid.org/0000-0003-4404-2870
Yoshimitsu, Makoto https://orcid.org/0000-0002-5935-0385
- License Information
-
More Information
Article History
Received: 3 January 2023
Revised: 13 March 2023
Accepted: 20 March 2023
First Online: 25 March 2023
Competing interests
: SF received honoraria from Takeda Pharmaceutical, Chugai Pharmaceutical, CSL Behring, Novartis Pharma, Otsuka Pharmaceutical, Sanofi, and Kyowa Kirin. YA received honoraria from Meiji Seika Pharma, JCR Pharmaceuticals, Novartis Pharma, Kyowa Kirin, AbbVie GK, and Astellas Pharma. MY received honoraria from Takeda Pharmaceutical, Chugai Pharmaceutical, CSL Behring, Novartis Pharma, Otsuka Pharmaceutical, Sanofi, and Daiichi-Sankyo.
